Oxford Asset Management’s Sutro Biopharma STRO Stock Holding History

Oxford Asset Management’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,285	Closed	-$14.9K	–	751
2025 Q1	$14.9K	Buy	+2,285	New	+$36K	0.01%	465
2020 Q1	$201K	Sell	1,969 -4,032	-67%	-$424K	0.03%	115
2019 Q4	$660K	Buy	6,001 +1,435	+31%	+$148K	0.02%	1090
2019 Q3	$415K	Buy	4,566 +2,144	+89%	+$216K	0.01%	1334
2019 Q2	$276K	Sell	2,422 -1,579	-39%	-$174K	0.01%	1469
2019 Q1	$456K	Sell	4,001 -1,506	-27%	-$157K	0.01%	1257
2018 Q4	$497K	Sell	5,507 -2,479	-31%	-$299K	0.01%	1202
2018 Q3	$1.2M	Buy	+7,986	New	+$1.21M	0.03%	928

Other funds holding STRO

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Oxford Asset Management's STRO Position: Q2 2025 in Review

Oxford Asset Management sold out of Sutro Biopharma (STRO) in Q2 2025, closing a stake of 2,285 shares — an estimated $14.9K sold.

Oxford Asset Management first reported a position in STRO in Q3 2018 and held it in 8 quarters. The position peaked at $1.2M in Q3 2018. 99 funds tracked by Wall St. Rank hold STRO as of Q2 2025.

Oxford Asset Management reported no remaining Sutro Biopharma position as of Q2 2025 after selling out during the quarter.
Oxford Asset Management sold 2,285 Sutro Biopharma shares in Q2 2025, an estimated $14.9K.
Oxford Asset Management first reported a position in Sutro Biopharma in Q3 2018 and held it in 8 quarters.
Oxford Asset Management's Sutro Biopharma position peaked at $1.2M in Q3 2018.
99 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2025.

Based on Oxford Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.